Lisocabtagene maraleucel in the treatment of relapsed/refractory large B-cell lymphoma

Frédérique St-Pierre, Leo I. Gordon*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations

Abstract

Lisocabtagene maraleucel (liso-cel) is one of the three US FDA-approved chimeric antigen receptor T-cell therapies for the treatment of relapsed/refractory (R/R) large B-cell lymphoma (LBCL). TRANSCEND is the landmark trial that led to the approval of liso-cel in the third-line setting for R/R diffuse LBCL, primary mediastinal B-cell lymphoma, follicular lymphoma grade 3B and transformed lymphoma. The TRANSFORM and PILOT studies evaluated the use of liso-cel in the second-line treatment of R/R LBCL. This review details the structure and manufacturing process of liso-cel that make it distinct from other approved chimeric antigen receptor constructs, outlines results from landmark trials of liso-cel in LBCL and discusses liso-cel toxicity.

Original languageEnglish (US)
Pages (from-to)19-28
Number of pages10
JournalFuture Oncology
Volume19
Issue number1
DOIs
StatePublished - Jan 1 2023

Keywords

  • CAR T-cell therapy
  • large B-cell lymphoma
  • lisocabtagene maraleucel

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Lisocabtagene maraleucel in the treatment of relapsed/refractory large B-cell lymphoma'. Together they form a unique fingerprint.

Cite this